OncoMatch/Clinical Trials/NCT05586074
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Is NCT05586074 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for leukemia, acute myeloid (aml).
Treatment: Clifutinib · LoDAC · Azacitidine · Decitabine · Ara-C±IDA · FLAG-IDA — A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: AML therapy — first-line
Subject is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant )
Cannot have received: FLT3 inhibitor
Subject has received prior treatment with other FLT3 inhibitors
Cannot have received: AML therapy
Subject has AML that has relapsed after or is refractory to more than 1 line of therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05586074 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FLT3 inhibitor, AML therapy disqualifies patients from enrollment.
Does this trial require FLT3?
Yes, FLT3 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages